Beam Therapeutics' pipeline, especially BEAM-101 for sickle cell disease, shows promise but remains in early stages with significant risks and high market expectations. Financially, BEAM has a ...

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

Oumuamua and Comet Borisov in 2017 and 2019, respectively, created a surge of interest. What were they? Where did they come ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...

"Chemical rockets that we use today, even with the extra speed boost from flying by planets, or from swinging by the sun for a boost, just don't have the ability to scale to useful interstellar speeds ...

France’s Framatome and IBA (Ion Beam Applications, Euronext), a specialist in particle accelerator technology and ...

along with its BEAM-302 base-editing candidate for alpha-1 antitrypsin deficiency (AATD) and BEAM-301, an in vivo lipid nanoparticle (LNP) therapy for glycogen storage disease 1a. Vertex's gene ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.